arrow
C

Carlo Sposito

fondazione irccs istituto nazionale tumori
H指数:36
被引数:6,844

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sex-Based Differences In Survival After Liver Transplantation For Colorectal Cancer Liver Metastases: A Multivariable Analysis

基于性别的结直肠癌肝转移肝移植后生存差异:一项多变量分析

2025-06-010
OAAI
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO

曲美木单抗和度伐利尤单抗作为微卫星不稳定性高、可切除的胃或胃食管结合部腺癌患者的新辅助治疗或非手术治疗策略:GONO开展的INFINITY研究

2025-03-018
PRE
Probability of Lymph Node Metastases in Patients Undergoing Adequate Lymphadenectomy during Surgery for Intrahepatic Cholangiocarcinoma: A Retrospective Multicenter Study
2024-10-160
OAAI
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
2024-07-010
OAAI
Multicentre, multi-cohort, single-arm phase II trial of tremelimumab and durvalumab as neoadjuvant or definitive treatment of patients (pts) with microsatellite instabilityhigh (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): The INFINITY study
2024-06-010
PRE
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study (vol 24, 436, 2024)
2024-05-060
OAAI
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024-04-085
OAAI
Surgical Treatment of Hepatocellular Carcinoma: Multicenter Competing-risk Analysis of Tumor-related Death Following Liver Resection and Transplantation Under an Intention-to-treat Perspective
2023-08-218
PRE